{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:14:47Z","timestamp":1791832487845,"version":"4.3.4"},"reference-count":146,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Mol Biol Rev"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p><jats:named-content content-type=\"genus-species\">Neisseria meningitidis<\/jats:named-content>is a Gram-negative microorganism that exists exclusively in humans and can cause devastating invasive disease. Although capsular polysaccharide-based vaccines against serogroups A, C, Y, and W135 are widely available, the pathway to a broadly protective vaccine against serogroup B has been more complex. The last 11 years has seen the discovery and development of the<jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>serogroup B (MnB) outer membrane protein factor H binding protein (fHBP) as a vaccine component. Since the initial discovery of fHBP, a tremendous amount of work has accumulated on the diversity, structure, and regulation of this important protein. fHBP has proved to be a virulence factor for<jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>and a target for functional bactericidal antibodies. fHBP is critical for survival of meningococci in the human host, as it is responsible for the primary interaction with human factor H (fH). Binding of hfH by the meningococcus serves to downregulate the host alternative complement pathway and helps the organism evade host innate immunity. Preclinical studies have shown that an fHBP-based vaccine can elicit serum bactericidal antibodies capable of killing MnB, and the vaccine has shown very encouraging results in human clinical trials. This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to<jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>, and its potential role as a vaccine for preventing MnB disease.<\/jats:p>","DOI":"10.1128\/mmbr.00056-12","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T14:14:41Z","timestamp":1369232081000},"page":"234-252","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":103,"title":["Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease"],"prefix":"10.1128","volume":"77","author":[{"given":"Lisa K.","family":"McNeil","sequence":"first","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Zagursky","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo L.","family":"Lin","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Murphy","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Zlotnick","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Hoiseth","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00051.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.102"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.061"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/428590"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)00279-7"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000154438.37306.ab"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20229"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441807"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/126.5.514"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.10.005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00044-4"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7566"},{"key":"e_1_3_2_19_2","first-page":"116","volume-title":"Proc. 13th Int. Pathog. Neisseria Conf.","author":"Bernfield L","year":"2002","unstructured":"BernfieldL FletcherLD HowellA FarleyJE ZagurskyR KnaufM ZlotnickG. 2002. Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116. Proc. 13th Int. Pathog. Neisseria Conf., Oslo, Norway."},{"key":"e_1_3_2_20_2","first-page":"124","volume-title":"Proc. 13th Int. Pathog. Neisseria Conf.","author":"Farley J","year":"2002","unstructured":"FarleyJ FletcherL BernfieldL HowellA KnaufM WeiseP XieX ZhangY. 2002. Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis, p 124. Proc. 13th Int. Pathog. Neisseria Conf., Oslo, Norway."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.083"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.065"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"e_1_3_2_27_2","first-page":"1005","volume-title":"Escherichia coli and Salmonella: cellular and molecular biology","author":"Wu HC","year":"1996","unstructured":"WuHC. 1996. Biosynthesis of lipoproteins, p 1005\u20131014. In NeidhardtFC . (ed), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed, vol 1. ASM Press, Washington, DC.","edition":"2"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/424464"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp634"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.029876-0"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.027"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.027995-0"},{"key":"e_1_3_2_34_2","first-page":"P505","volume-title":"Abstr. 27th Annu. Meet. Eur. Soc. Paediatr. Infect. Dis.","author":"Anderson A","year":"2009","unstructured":"AndersonA HoisethS MurphyE AndrewL McNeilL AbadR VazquezJ VogelU FroschM JansenK. 2009. Epidemiology of the serogroup B N. meningitidis (MNB) factor H binding protein and implications for vaccine development, p P505. Abstr. 27th Annu. Meet. Eur. Soc. Paediatr. Infect. Dis., Brussels, Belgium."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.12.052"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033016"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.072"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.092"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/597806"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001302"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70251-6"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.025"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.0.14564"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05604-11"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00055-11"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001027"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.075"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12104-009-9153-9"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808831200"},{"key":"e_1_3_2_50_2","first-page":"O61","volume-title":"Proc. 16th Int. Pathog. Neisseria Conf.","author":"Mascioni A","year":"2008","unstructured":"MascioniA NovikovaE BentleyBE McNeilLK MurphyE CamardaR LinS Ddilts FinkP MininniTL HoisethS TsaoD ZlotnickGW. 2008. Determination of the domain and solution structure of rLP2086, a meningococcal vaccine candidate and human factor H binding protein, p O61. Proc. 16th Int. Pathog. Neisseria Conf., Rotterdam, The Netherlands."},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C800214200"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1107\/S1744309111006154"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07769"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002234"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00740-0"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70132-X"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.002"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540600643203"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)80300-8"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1824"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.671"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01561-08"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.060"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.06.016"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/jemt.10047"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-15248"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.149.8.2592","article-title":"Ultrastructures and interactions of complement factors H and I","volume":"149","author":"DiScipio RG","year":"1992","unstructured":"DiScipioRG. 1992. Ultrastructures and interactions of complement factors H and I. J. Immunol. 149:2592\u20132599.","journal-title":"J. Immunol"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.02.005"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)55379-5"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.122.1.75","article-title":"Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1H for cell-bound C3b","volume":"122","author":"Kazatchkine MD","year":"1979","unstructured":"KazatchkineMD FearonDT AustenKF. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1H for cell-bound C3b. J. Immunol. 122:75\u201381.","journal-title":"J. Immunol"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.640"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00849-10"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00891-10"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.082"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05182-11"},{"key":"e_1_3_2_76_2","first-page":"94","volume-title":"Proc. 18th Int. Pathog. Neisseria Conf.","author":"McNeil LK","year":"2010","unstructured":"McNeilLK ZlotnickGW ZhaoX AndersonAS JansenKU. 2010. Anti-fHBP antibodies elicited after immunization with a recombinant fHBP vaccine candidate (rLP2086) can displace human factor H from the surface of serogroup B meningococci, p 94. Proc. 18th Int. Pathog. Neisseria Conf., Banff, Canada."},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003470"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1086\/656741"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.85"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00304-10"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70087-7"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.065"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61713-3"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181f59f6d"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01191-08"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.3.616-623.2001"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.40.1.257-264.1983"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-147-8-2321"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2008.06.010"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.054957-0"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01308-09"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00367-08"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1086\/528994"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5606"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.12.005"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.075"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05956-11"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.02.021"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4489"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep00341"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01071-08"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01313-08"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.051"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.10.6838-6845.2005"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.056"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.056"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45529-0"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.038"},{"key":"e_1_3_2_110_2","first-page":"O026","volume-title":"Abstr. 10th Eur. Meningococci Dis. Soc. Meet.","author":"Anderson AS","year":"2009","unstructured":"AndersonAS. 2009. Development of a factor H binding protein vaccine for broad protection against invasive Neisseria meningitidis serogroup B (MNB) disease, p O026. Abstr. 10th Eur. Meningococci Dis. Soc. Meet., Manchester, United Kingdom."},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2008.04.002"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3140"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.098"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1086\/514821"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1093\/gbe\/evr119"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00241-3"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.21.2795"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000148928.10057.86"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00403-08"},{"key":"e_1_3_2_120_2","first-page":"19","volume-title":"Abstr. 11th EMGM Meeting","author":"McNeil LK","year":"2011","unstructured":"McNeilLK ZlotnickG CamposanoE LoganSM NovikovaEG ZhaoXJ AndersonAS PrideMW JansenKU. 2011. Development of a meningococcal antigen surface expression (Measure) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis, p 19\u201320. Abstr. 11th EMGM Meeting, Ljubljana, Slovenia."},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00529-09"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_2_124_2","first-page":"197","article-title":"Control of meningococcal meningitis with meningococcal vaccines","volume":"48","author":"Artenstein MS","year":"1975","unstructured":"ArtensteinMS. 1975. Control of meningococcal meningitis with meningococcal vaccines. Yale J. Biol. Med. 48:197\u2013200.","journal-title":"Yale J. Biol. Med"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197002192820803"},{"key":"e_1_3_2_126_2","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70","volume":"45","author":"Gold R","year":"1971","unstructured":"GoldR ArtensteinMS. 1971. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull. World Health Organ. 45:279\u2013282.","journal-title":"Bull. World Health Organ"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31820a8b3c"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.6.15482"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31826327e4"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31827b0d24"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.021"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.18500"},{"key":"e_1_3_2_133_2","unstructured":"Pfizer. 2011 posting date. Study evaluating safety tolerability and immunogenicity of meningococcal B vaccine in healthy infants. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00798304?term=NCT00798304&rank=1."},{"key":"e_1_3_2_134_2","unstructured":"JansenKU. 2011 posting date. Vaccines and Related Biological Products Advisory Committee meeting presentation: VRBPAC meeting to discuss approaches to licensure of meningococcal serogroup B vaccines. http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm251454.htm."},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23222"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.48"},{"key":"e_1_3_2_137_2","unstructured":"van der AvoortHGAM BerbersGAM van BinnendijkRS BootHJ FeltkampMCW FriesemaIHM de GreeffSC Hahn\u00e9SJM KemmerenJM van der KlisFRM KramerMA van LierEA van der MaasNAT de MelkerHE MooiFR ReubsaetF SchoulsLM De VoerRR. 2010. The National Immunisation Programme in the Netherlands. Developments in 2009. RIVM National Institute for Public Health and the Environment. http:\/\/www.rivm.nl\/bibliotheek\/rapporten\/210021012.pdf."},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.19983"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.019"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.039"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.048"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.095"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.064"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00038-06"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-1048"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg500"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msm092"}],"container-title":["Microbiology and Molecular Biology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/MMBR.00056-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/MMBR.00056-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T21:40:14Z","timestamp":1688247614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/MMBR.00056-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1128\/MMBR.00056-12"],"URL":"https:\/\/doi.org\/10.1128\/mmbr.00056-12","relation":{},"ISSN":["1092-2172","1098-5557"],"issn-type":[{"value":"1092-2172","type":"print"},{"value":"1098-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"2013-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}